Neurocrine (NBIX) $2.5B Deal for Soleno Therapeutics

Neurocrine Biosciences (NBIX) is nearing a deal exceeding $2.5 billion to acquire Soleno Therapeutics. Soleno Therapeutics has developed the first commercialized drug aimed at treating extreme hunger associated with Prader-Willi syndrome. This acquisition could enhance Neurocrine's product portfolio and expand its market capabilities in the biotech sector. The transaction highlights ongoing consolidation within the pharmaceutical industry, particularly focused on innovative treatments for rare diseases.